Keywords
Glomerulonephritis
Rapid progressive glomerulonephritis
End stage kidney disease
Categories
Abstract
Anti–glomerular basement membrane (anti-GBM) antibody disease is an autoimmune disorder. The majority of patients develop widespread glomerular crescent formation, presenting with features of rapidly progressive glomerulonephritis (RPGN). The etiology is unclear. The treatment depends on the creatinine level at presentation, dialysis dependency, and pulmonary involvement to decide on plasmapheresis, glucocorticoid, and immunosuppressive therapy. We report a case of a 17-year-old lady who presented features of RPGN requiring intermittent dialysis, renal biopsy, and serology showing features of anti-GBM glomerulonephritis (GN).
References
McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol 2017; 12:1162.
Savage CO, Pusey CD, Bowman C, et al. Anti-glomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301.
Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033
Touzot M, Poisson J, Faguer S, Ribes D, Cohen P, Geffray L, Anguel N, François H, Karras A, Cacoub P, Durrbach A, Saadoun D: Rituximab in anti-GBM disease: A retrospective study of 8 patients. J Autoimmun 60: 74–79, 2015
Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 139–274, 2012
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Journal of Clinical and Translational Nephrology